archive-com.com » COM » A » AGENDIA.COM

Total: 235

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • St. Gallen Guidelines | Agendia
    Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 Publication Name Annals of Oncology Author s A Goldhirsch W C Wood A S Coates R D Gelber B Thu rlimann H J Senn Panel May 23 2011 The 12th St Gallen International Breast Cancer Conference 2011 Expert Panel adopted a new approach to the classification of patients for therapeutic purposes based on the recognition of intrinsic biological subtypes within the breast cancer spectrum For practical purposes these Continued Thresholds for therapies highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer Publication Name Annals of Oncology Author s Goldhirsch A Ingle JN Gelber RD et al June 17 2009 The 11th St Gallen Switzerland expert consensus meeting on the primary treatment of early breast cancer in March 2009 maintained an emphasis on targeting adjuvant systemic therapies according to subgroups defined by predictive markers Any positive level of estrogen receptor Continued Categories Abstract Poster 18 Accreditation 1 BluePrint 9 Clinical Studies 8 ColoPrint 5 Cost Effectiveness 6 Development 8 Impact Study 2 MammaPrint 40 MINDACT 5 News 56 Predictive 3 Press Release 53 Publications 58 Review Article 10 St Gallen Guidelines

    Original URL path: http://www.agendia.com/category/guidelines/ (2016-05-01)
    Open archived version from archive


  • TargetPrint | Agendia
    investigate the correlation of TargetPrint with local and central immunohistochemistry fluorescence in situ hybridization assessment of estrogen ER progesterone PgR and human epidermal growth factor receptor 2 HER2 in the first 800 patients enrolled in the MINDACT trial PATIENTS Continued Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients with early stage breast cancer Publication Name International Journal of Molecular Medicine Author s Heidrun Gevensleben Uwe Jochen Gohring Reinhard Buttner Lukas C Heukamp Georg Kunz Thomas Dimpfl Christian Jackisch Olaf Ortmann Ute Susann Albert Richard Bender Femke De Snoo Oscar Krijgsman Annuska M Glas July 30 2010 The 70 gene expression profile MammaPrint is a powerful prognostic indicator for disease outcome in breast cancer patients with improved prediction of recurrence risk compared to currently used guidelines The microarray based test TargetPrint further provides reliable quantitative assessment of mRNA expression Continued Microarray Based Determination of Estrogen Receptor Progesterone Receptor and HER2 Receptor Status in Breast Cancer Publication Name Clinical Cancer Research Author s Paul Roepman Hugo M Horlings Oscar Krijgsman Marleen Kok Jolien M Bueno de Mesquita Richard Bender Sabine C Linn Annuska M Glas and Marc J van de Vijver November 3 2009 Purpose The level of estrogen receptor ER progesterone receptor PR and HER2 aids in the determination of prognosis and treatment of breast cancer Immunohistochemistry is currently the predominant method for assessment but differences in methods and interpretation can substantially affect Continued Microarray based determination of ER PR and HER2 receptor status validation and comparison with IHC assessments Publication Name Poster SABCS 2008 Author s Paul Roepman Hugo Horlings Oscar Krijgsman Jolien Bueno de Mesquita Richard Bender Sabine Linn Annuska Glas and Marc van de Vijver January 15 2009 In breast cancer patients the level of expression of estrogen receptor ER progesterone receptor PR and

    Original URL path: http://www.agendia.com/category/targetprint/ (2016-05-01)
    Open archived version from archive

  • Treatment Impacts | Agendia
    positive tumors benefit from hormonal therapies We hypothesized that a subgroup of breast cancer patients expresses estrogen receptor a ERa but fails to respond to hormonal therapy due to the expression of Continued Molecular subtyping of early stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy Publication Name Breast Cancer Research and Treatment Author s Stefan Glück Femke de Snoo Justine Peeters Lisette Stork Sloots George Somlo June 1 2013 The aim of this study was to analyze the correlation between the pathologic complete response pCR rate after neoadjuvant chemotherapy and long term outcome distant metastases free survival DMFS in patients with early stage breast cancer using BluePrint and MammaPrint molecular subtyping versus Continued Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients with early stage breast cancer Publication Name International Journal of Molecular Medicine Author s Heidrun Gevensleben Uwe Jochen Gohring Reinhard Buttner Lukas C Heukamp Georg Kunz Thomas Dimpfl Christian Jackisch Olaf Ortmann Ute Susann Albert Richard Bender Femke De Snoo Oscar Krijgsman Annuska M Glas July 30 2010 The 70 gene expression profile MammaPrint is a powerful prognostic indicator for disease outcome in breast cancer patients with improved prediction of recurrence risk compared to currently used guidelines The microarray based test TargetPrint further provides reliable quantitative assessment of mRNA expression Continued Use of a 70 Gene Signature to predict prognosis of patients with node negative breast cancer a prospective community based feasibility study RASTER Publication Name Lancet Oncology Author s Jolien M Bueno de Mesquita MD Prof Wim H van Harten MD Valesca P Retel MSc Laura J van t Veer PhD Prof Frits SAM van Dam PhD Kim Karsenberg MSc Kirsten FL Douma MSc Harm van Tinteren PhD Johannes L Peterse MD Jelle Wesseling MD Tin S

    Original URL path: http://www.agendia.com/category/treatment-impacts/ (2016-05-01)
    Open archived version from archive

  • Validation | Agendia
    heterogeneity Indicators such as sensitivity specificity positive predictive value and negative predictive value are typically used to define the clinical performance of a diagnostic Continued A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study Publication Name International Journal of Cancer Author s C A Drukker J M Bueno de Mesquita V P Retèl W H van Harten H van Tinteren J Wesseling R M H Roumen M Knauer L J van t Veer G S Sonke E J T Rutgers M J van de Vijver S C Linn January 31 2013 The 70 gene signature MammaPrint has been developed on retrospective series of breast cancer patients to predict the risk of breast cancer distant metastases The microarRAy prognoSTics in breast cancER RASTER study was the first study designed to prospectively evaluate the performance of the 70 gene Continued Comparison of Molecular Subtyping with BluePrint MammaPrint and TargetPrint to Local Clinical Subtyping in Breast Cancer Patients Publication Name Annals of Surgical Oncology Author s Bichlien Nguyen Pino G Cusumano Kenneth Deck Deborah Kerlin Agustin A Garcia Julie L Barone Edgardo Rivera Katharine Yao Femke A de Snoo Jeroen van den Akker Lisette Stork Sloots Daniele Generali August 15 2012 Purpose To compare breast cancer subtyping with the three centrally assessed microarray based assays BluePrint MammaPrint and TargetPrint with locally assessed clinical subtyping using immunohistochemistry IHC and fluorescence in situ hybridization FISH Methods BluePrint MammaPrint and TargetPrint were all performed on Continued Gene Expression Profiles from Formalin Fixed Paraffin Embedded Breast Cancer Tissue Are Largely Comparable to Fresh Frozen Matched Tissue Publication Name PLOS ONE Author s Lorenza Mittempergher Jorma J de Ronde Marja Nieuwland Ron M Kerkhoven Iris Simon Emiel J Th Rutgers Lodewyk F A Wessels Laura J Van t Veer February 1 2011 Background and Methods Formalin Fixed Paraffin Embedded FFPE samples represent a valuable resource for cancer research However the discovery and development of new cancer biomarkers often requires fresh frozen FF samples Recently the Whole Genome WG DASL cDNA mediated Annealing Selection Continued Identification of a low risk subgroup of HER 2 positive breast cancer by the 70 gene prognosis signature Publication Name British Journal of Cancer Author s M Knauer F Cardoso J Wesseling PL Bedard SC Linn EJT Rutgers and LJ van t Veer September 20 2010 BACKGROUND Overexpression of HER 2 is observed in 15 25 of breast cancers and is associated with increased risk of recurrence Current guidelines recommend trastuzumab and chemotherapy for most HER 2 positive patients However the majority of patients does not recur and might thus Continued Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients with early stage breast cancer Publication Name International Journal of Molecular Medicine Author s Heidrun Gevensleben Uwe Jochen Gohring Reinhard Buttner Lukas C Heukamp Georg Kunz Thomas Dimpfl Christian Jackisch Olaf Ortmann Ute Susann Albert Richard Bender Femke De Snoo Oscar Krijgsman Annuska M Glas July 30 2010 The 70 gene expression profile MammaPrint is a

    Original URL path: http://www.agendia.com/category/validation/ (2016-05-01)
    Open archived version from archive

  • Video | Agendia
    KARE Minneapolis St Paul 2013 This TV report tells how you can know your breast cancer better through this genomic personalized medicine test which is part of the Symphony suite of breast cancer tests Breast cancer survivor describes how Symphony helped her avoid chemotherapy to the House Medical Technology Caucus on Capital Hill Publication Name Video January 31 2013 December 2012 AdvaMed Dx Categories Abstract Poster 18 Accreditation 1 BluePrint

    Original URL path: http://www.agendia.com/category/video/ (2016-05-01)
    Open archived version from archive

  • Hiring Process | Agendia
    outline the typical hiring process for new candidates 1 Review Career Opportunities Review all current opportunities 2 Apply Did you find a job that interests you Wonderful We encourage you to apply for all positions of interest that match your experience and education P lease send an email to Human Resources at jobs agendia com 3 Assessment This is the time for an Agendia representative to examine applicants skills experience and education against the requirements for an open role 4 Interview An Agendia representative will contact the most qualified candidates and invite them to an interview This stage can include a phone interview and one or two rounds of in person interview s 5 Job Offer and Welcome Agendia will select the candidate that is the best fit for the role a hiring manager will contact the selected candidate to extend the job offer Accepted our offer Welcome to Agendia and congratulations We will provide you with information that you need to ensure you have everything that you need to be ready for your first day and complete your final employment forms We d Love To Hear From You Name Email Questions Comments Concerns Questions Comments Concerns Phone This field

    Original URL path: http://www.agendia.com/careers/hiring-process/ (2016-05-01)
    Open archived version from archive

  • What you can expect | Agendia
    What you can expect Our Locations Agendia offers competitive insurance and benefits options Learn more by clicking on the links below Insurance Benefits Agendia offers a wide range of benefits for you and your family Medical HMO PPO Dental HMO PPO Vision Employer Sponsored Short term disability Long term disability Basic Life Insurance Accidental Death Dismemberment Business Travel Accident Insurance Supplemental Life Insurance Supplemental Accidental Death Dismemberment Flexible Spending Healthcare Flexible Spending Account Dependent Care Flexible Spending Account Work Life Programs Personal time off plan PTO Paid absences for Bereavement Jury Duty Company paid holidays 24 Hour Fitness discounts Employee driven Wellness program Financial Fitness 401 k and Roth Retirement Plan with combined 50 company match on the first 6 529 College Savings Plan Credit Union Extras Gift certificate on employees birthday Monthly socials ice cream or fresh fruit Lunch Learns and Vendor Fairs On site dry cleaning On site car wash Employee appreciation events Pet Insurance Employees discount offers and services Community Involvement Employee Referral Program Employee annual events Lab Week Holiday event Health Fair We d Love To Hear From You Name Email Questions Comments Concerns Questions Comments Concerns Email This field is for validation purposes and should

    Original URL path: http://www.agendia.com/careers/what-you-can-expect/ (2016-05-01)
    Open archived version from archive

  • Our Locations | Agendia
    Locations Home Hiring Process What you can expect Our Locations US Headquarters 22 Morgan Irvine CA 92618 ph 888 321 2732 European Headquarters Science Park 406 1098 XH Amsterdam the Netherlands ph 31 0 20 462 1500 We d Love To Hear From You Name Email Questions Comments Concerns Questions Comments Concerns Comments This field is for validation purposes and should be left unchanged Resources Online Ordering Publications Studies Physician

    Original URL path: http://www.agendia.com/careers/our-locations/ (2016-05-01)
    Open archived version from archive



  •